#neostem

[pknoepfl]

CIRM 2.0 starts off with a bang

CIRM 2.0 starts off with a bang

CIRM has reinvented itself in a new form, CIRM 2.0, under the leadership of its new President Randy Mills.

CIRM is almost like a stem cell that has changed into another new kind of stem cell. Us scientists could see the change coming in the “programming” at CIRM in terms of how it was operating as the 2.0 version, but what would it bring in practical terms?

We are starting to see the new CIRM…

View On WordPress

[pknoepfl]

As Predicted, Big News For California Stem Cell, Inc.: Purchased by NeoStem

As Predicted, Big News For California Stem Cell, Inc.: Purchased by NeoStem

Late last year I was hearing some exciting things about California Stem Cell, Inc. under the leadership of Hans Keirstead.

In fact, I thought a big move for California Stem was in the cards for 2014 and looking into my stem cell crystal ball, I went so far as to make that one of my top 10 stem cell predictions for 2014.

Today, that prediction came true with the purchaseof California Stem by stem…

View On WordPress

[patthehero]

View this post on Instagram

#neostem

[biochemistries]

The scientifically naive Vatican finds the concept of adult stem cells attractive simply because embryos are not involved — yet it ignores the ethical implications of false hope.

Nature was appalled in April by the heavy-handed tactics of the Catholic church in its public courtship of New York-based company Neostem, which is pushing Very Small Embryonic-Like stem cells (VSELs) to clinical trial — prematurely, in the eyes of many scientists. 

The company itself acknowledges the "conflicting and controversial data" (mainly that other labs following their protocol cannot reproduce their results).

‘‘We found that every step of the way, we could not confirm the results of the Ratajczak group,’’ says Irving Weissman, Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine and the senior author of an article in Stem Cell Reports this week (Stanford press release available here).

As well as being dismissive of this discordant body of literature, the company is now looking to move to clinical trial with the cells, to which the company acquired worldwide exclusive technology rights in 2007.

Henry Nichols, writing for Cell Stem Cell warns that pushing on the commercial while disregarding the research basis of VSELs could be harmful beyond the letdown to patients, potentially damaging the field as a whole. ■ Henry Nichols, VSELs: Is Ideology Overtaking Science? Cell Stem Cell, vol 13 (2013) ■ Miyanishi et al., Do Pluripotent Stem Cells Exist in Adult Mice as Very Small Embryonic Stem Cells?OA Stem Cell Reports, vol 1 (2013)

[redchip-blog]

This week's episode of "The RedChip Money Report" features interviews with Seth Grae, CEO of Lightbridge Corp. (NASDAQ: LTBR), a U.S. nuclear energy company; Dr. Robin Smith, Chairman and CEO of NeoStem, Inc. (NYSE MKT: NBS), a stem cell therapy company; and Robert Miller, CEO of Abakan, Inc. (OTCQB: ABKI), a developer and manufacturer of advanced nanocomposite materials. "The RedChip Money Report"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies. "The RedChip Money Report"™ airs Saturdays at 2:30 p.m. on Fox Business News, a premium business network reaching more than 65 million homes nationwide. The weekly program also airs on My Family TV and TUFF TV.